Teva Pharmaceutical (TEVA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.02
- EPS estimate
- $0.05
- EPS surprise
- −60.04%
- Revenue surprise
- +6.50%
- Revenue
- $4.3B
- Revenue estimate
- $4.0B
- Reported
- Jul 29, 2026
Teva reported Q2 2026 results on July 29, 2026. Earnings per share were $0.02, short of the $0.05 estimate by 60.04%. Revenue of $4.3 billion beat the $4.0 billion consensus by 6.50%. Compared with Q2 2025, EPS fell from $0.66, while revenue rose from $4.2 billion. The quarter's EPS was the lowest in the table, down from $0.50 in Q1 2026.
Earlier years were steady. Annual EPS was $2.53 in 2022, $2.56 in 2023, $2.49 in 2024 and $2.89 in 2025. Annual revenue rose each year, from about $15.0 billion in 2022 to about $17.2 billion in 2025. Q4 2025 set the revenue high in the table at $4.6 billion, and Q4 2023 the EPS high at $1.00. The first half of 2026 adds up to $0.52 per share, against $1.18 a year earlier. Over the last 20 quarters, Teva topped the EPS estimate 13 times. Apart from Q2 2026, the largest miss was Q1 2023, at 28.19%.
Teva reported Q3 between November 3 and November 8 in each of the past four years. That points to early November 2026 for the next report. It will show whether earnings move back toward the levels of earlier quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | $0.05 | $0.02 | −60.04% | $4.3B | SEC |
| Q1 2026 | Apr 29, 2026 | $0.46 | $0.50 | +9.42% | $3.8B | SEC |
| Q4 2025 | Jan 28, 2026 | $0.64 | $0.93 | +45.47% | $4.6B | SEC |
| Q3 2025 | Nov 5, 2025 | $0.69 | $0.78 | +13.03% | $4.5B | SEC |
| Q2 2025 | Jul 30, 2025 | $0.62 | $0.66 | +7.02% | $4.2B | SEC |
| Q1 2025 | May 7, 2025 | $0.46 | $0.52 | +12.43% | $3.9B | SEC |
| Q4 2024 | Jan 29, 2025 | $0.71 | $0.71 | +0.38% | $4.2B | SEC |
| Q3 2024 | Nov 6, 2024 | $0.66 | $0.69 | +4.34% | $4.3B | SEC |
| Q2 2024 | Jul 31, 2024 | $0.55 | $0.61 | +10.51% | $4.2B | SEC |
| Q1 2024 | May 8, 2024 | $0.51 | $0.48 | −6.58% | $3.8B | SEC |
| Q4 2023 | Jan 31, 2024 | $0.77 | $1.00 | +30.29% | $4.5B | SEC |
| Q3 2023 | Nov 8, 2023 | $0.61 | $0.60 | −1.28% | $3.9B | SEC |
| Q2 2023 | Aug 2, 2023 | $0.53 | $0.56 | +6.63% | $3.9B | SEC |
| Q1 2023 | May 10, 2023 | $0.56 | $0.40 | −28.19% | $3.7B | SEC |
| Q4 2022 | Feb 8, 2023 | $0.72 | $0.71 | −0.70% | $3.9B | SEC |
| Q3 2022 | Nov 3, 2022 | $0.62 | $0.59 | −4.21% | $3.6B | — |
| Q2 2022 | Jul 26, 2022 | $0.58 | $0.68 | +16.96% | $3.8B | — |
| Q1 2022 | May 3, 2022 | $0.55 | $0.55 | +0.16% | $3.7B | — |
| Q4 2021 | Feb 9, 2022 | $0.73 | $0.77 | +4.93% | $4.1B | — |
| Q3 2021 | Oct 27, 2021 | $0.64 | $0.59 | −8.47% | $3.9B | — |
Quarterly revenue
Frequently asked questions
When did Teva Pharmaceutical (TEVA) last report earnings?
Teva Pharmaceutical last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did TEVA beat earnings estimates?
No. Teva Pharmaceutical reported EPS of $0.02 for Q2 2026 against a $0.05 estimate — a 60.04% miss.
How much revenue did TEVA report last quarter?
Teva Pharmaceutical reported $4.3B in revenue for Q2 2026, against a consensus estimate of $4.0B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.